Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Founder, execs of drug company guilty in conspiracy that fed opioid crisis

Published 05/02/2019, 08:05 PM
Updated 05/02/2019, 08:05 PM
© Reuters. FILE PHOTO: John Kapoor the billionaire founder of Insys Therapeutics Inc. leaves the federal courthouse in Boston

© Reuters. FILE PHOTO: John Kapoor the billionaire founder of Insys Therapeutics Inc. leaves the federal courthouse in Boston

By Nate Raymond

BOSTON (Reuters) - The founder of Insys Therapeutics Inc on Thursday became the highest-ranking pharmaceutical executive to be convicted in a case tied to the U.S. opioid crisis, when he and four colleagues were found guilty of participating in a scheme to bribe doctors to prescribe an addictive painkiller.

A federal jury in Boston found John Kapoor, the drugmaker's former chairman, and his co-defendants guilty of racketeering conspiracy for engaging in a scheme that also misled insurers into paying for the drug.

Kapoor's 2017 arrest came on the same day U.S. President Donald Trump declared the epidemic that has caused tens of thousands of overdose deaths annually a public health emergency.

Kapoor, 76, was found guilty of running a wide-ranging scheme to bribe doctors nationwide by retaining them to act as speakers at sham events at restaurants ostensibly meant to educate clinicians about its fentanyl spray, Subsys.

Prosecutors said Kapoor also directed efforts to defraud insurers who were reluctant to pay for Subsys. His co-defendants were former Insys executives and managers Michael Gurry, Richard Simon, Sunrise Lee and Joseph Rowan.

They face up to 20 years in prison. They denied wrongdoing, and defense lawyers signaled plans to appeal.

"Dr. Kapoor is disappointed in the verdict, as are we," Beth Wilkinson, Kapoor's lead attorney, said in a statement. "Four weeks of jury deliberations confirm that this was far from an open-and-shut case."

The U.S. Food and Drug Administration approved Subsys in 2012 only for use in treating severe cancer pain. Yet prosecutors claimed doctors who took bribes often prescribed Subsys to patients without cancer, helping boost sales for Chandler, Arizona-based Insys.

Fentanyl is an especially potent opioid, 100 times stronger than morphine.

Kapoor's lawyers acknowledged Insys paid doctors but contended he believed they were being legally paid to discuss Subsys' benefits.

Wilkinson in her opening statement in January told jurors Kapoor had no knowledge of "side deals" being cut with doctors. She said a former executive turned government witness, Alec Burlakoff, kept Kapoor in the dark about them.

Burlakoff, Insys' ex-vice president of sales, and Michael Babich, its former chief executive, testified against Kapoor after pleading guilty to participating in the scheme.

Jurors during the trial watched a rap video Insys produced for its sales staff describing its strategies to boost sales that starred Burlakoff dressed as a dancing bottle of Subsys.

Witnesses also testified that Lee, an ex-stripper turned Insys regional sales director, gave a lap dance to a doctor at a Chicago club while pushing him to prescribe Subsys.

© Reuters. FILE PHOTO: John Kapoor the billionaire founder of Insys Therapeutics Inc. leaves the federal courthouse in Boston

Insys in August said it had agreed to pay at least $150 million in a related settlement with the U.S. Justice Department. In a statement on Thursday, it said the case involved "the actions of a select few former employees."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.